Degarelix CAS 214766-78-6 API Active Pharmaceutical Ingredient

Product Description:

Product Name:Degarelix CAS 214766-78-6

Synonyms:

Degarelix acetate(FE-200486,Degarelix);

N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-4-[2,6-dioxohexahydropyrimidin-Chemicalbook4(S)-ylcarboxamido]-L-phenylalanyl-4-ureido-D-phenylalanyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamideacetate;

Chemical & Physical Properties

Appearance:White to off white powder

Assay: 99%+

Pka:10.38±0.40

Density:1.325±0.06 g/cm³

Solubility:DMSO:10.0(Max Conc. mg/mL);6.13(Max Conc. mM)

H₂O:25.0(Max Conc. mg/mL);15.32(Max Conc. mM)

Application

Digarek acetate is a synthetic antagonist of the gonadotropin-releasing hormone (GnRH) receptor, which can reduce the release of gonadotropin and testostero-ne through reversible binding to the GnRH receptor of the pituitary gland, thus playing an anti-prostate cancer role.Digarek acetate is a gonadotropin-releasing hormone receptor blocker that has been approved for the treatment of advanced (hormone-dependent) prostate cancer in the United States and Europe, respectively, and for the treatment of prostate cancer in Japan.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.